Log In Sign up
The largest database of trusted experimental protocols

Id now covid 19 assay

Manufactured by Abbott
Visit Supplier
Sourced in United States

The ID NOW COVID-19 assay is a molecular in vitro diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The assay is designed to be used with the ID NOW Instrument, a compact, lightweight, and portable molecular testing platform.

Automatically generated - may contain errors

Lab products found in correlation

Realtime sars cov 2 assay, by Abbott (2 mentions) Taqpath covid 19 combo kit, by Thermo Fisher Scientific (2 mentions) Magna pure 96, by Roche (2 mentions) Liaison mdx, by DiaSorin (1 mentions) Simplexa covid 19 direct assay, by DiaSorin (1 mentions) M2000 system, by Abbott (1 mentions)

7 protocols using id now covid 19 assay

1

Evaluating COVID-19 Serology in Hematological Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols
This is a retrospective study comprising 101 unique serum samples from HM and HM+CoV patients collected between March and October 2020, including samples from 30 MM patients with measurable M-spikes, 8 HM + CoV cases and the remaining cases (n = 63) from patients in various t-MAb treatments (Daratumumab n = 45, Rituximab n = 10, Obinutuzumab n = 5 and Brentuximab n = 3) (Figure 1a). All were remnant samples in the laboratory after routine testing. The UT Southwestern Medical Center’s Institutional Review Board (IRB) approved this study (STU-2020-0366; 04/17/2020).
Serologic assessment for SARS-CoV-2 was performed by Abbott Architect IgG CMIA (nucleocapsid), Ansh Labs IgG ELISA test on Dynex DSX (S1/S2) and Ortho Vitros immunometric total antibody (including IgA, IgM and IgG, S1) tests (Table S1). In addition, we spiked 4 t-MAbs at clinically relevant concentrations (0.15 to 0.5 g/L) or equal volume of saline for controls in three COVID-19-positive and three routine random-pooled samples (with no record of COVID-19 PCR positivity) and tested for SARS-CoV-2 serology to ascertain their reactivity (Figure 1b). M2000 Abbott Real-Time SARS-CoV-2 assay or the Abbott ID NOW COVID-19 assay confirmed infection with SARS-CoV-2 in the HM patients [12 (link)]. Cross reactivity was assessed in terms of positive or reactive results for the above tested assays in the non-COVID+HM specimens.
Mahimainathan L., Narasimhan M., Corchado R., Patel H., Kansagra A., Devaraj S., Geethakumari P.R, & Muthukumar A. (2020). Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies. Diagnostics, 10(12), 992.
+ Open protocol
+ Expand
2

Comparison of ID NOW and Simplexa COVID-19 Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
The ID NOW COVID-19 assay (Abbott, Chicago, Il, USA) is an isothermal nucleic acid amplification-based. The assay was performed directly from the dry swab in the ED or by transferring 200 microliters of VTM to elution buffer in the sample base and then mixed for 10 seconds per instructions for use at the microbiology laboratory.
The Simplexa COVID-19 direct assay (Diasorin, Saluggia, Italy) was chosen as RT-PCR reference test and was performed with the DiaSorin LIAISON® MDX according to the manufacturer's instructions for use. A 50 μl volume of Simplexa COVID-19 Direct kit reaction mix (MOL415 0) was added to the “R” well of the 8-well direct amplification disc followed by addition of 50 μl of non extracted nasopharyngeal swab sample to the “SAMPLE” well. Fluorescent probes are used together with corresponding forward and reverse primers to amplify two different regions of the SARS-CoV-2 genome: ORF1ab and S gene. Data collection and analysis were performed with LIAISON® MDX Studio software. CT values were collected from MDX software.
NguyenVan J.C., Gerlier C., Pilmis B., Mizrahi A., Péan de Ponfilly G., Khaterchi A., Enouf V., Ganansia O, & Le Monnier A. (2021). Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department. Journal of Clinical Virology, 145, 105021.
+ Open protocol
+ Expand
3

SARS-CoV-2 Testing in Incarcerated Individuals

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Individuals who entered the jail or who were incarcerated already who developed influenza-like illness were tested for SARS-CoV-2. Collected specimens during incarceration were processed in the Stroger Hospital laboratory using the m2000 system (Abbott Laboratories, Chicago, Illinois) [7 (link)]. Newly detained individuals were tested using the ID NOW COVID-19 assay (Abbott) starting on 20 April 2020; however, these specimens were not available for analysis. Swabs collected during incarceration for a variety reasons available for genomic analysis included: (1) people under investigation, (2) as part of intake clearance at day 14, (3) prior to prison transfer, (4) pre-procedure, (5) admission to higher level of care, (6) postquarantine clearance, (7) detainee request, or (8) exposure to a case.
Adediran T., Zawitz C., Piriani A., Bendict E., Thiede S., Barbian H., Aroutcheva A., Green S.J., Welbel S., Weinstein R.A., Snitkin E, & Popovich K.J. (2023). Genomic Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a County Jail. Open Forum Infectious Diseases, 11(2), ofad675.
+ Open protocol
+ Expand
4

Diagnostic Testing for COVID-19 in the ED

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients presenting to the ED who were tested for acute COVID-19 infection while in the ED or within two hours of their triage temperature (if they were admitted and tested after they left the ED) were included in the study population. Data collected from the EMR using standard queries included clinical characteristics including initial temperature, the presence or recent history of COVID-19–related symptoms, and COVID-19 test results.
The health system used two diagnostic tests during the study period to assess for SARS-CoV-2, the Abbot ID Now COVID-19 assay, and the ePLex SARS-CoV-2. The Abbot ID Now assay is a rapid test that detects the presence of virus RNA from direct nasal, nasopharyngeal, or throat swabs. The ePLex SARS-CoV-2 test detects virus particles in clinical samples collected with a nasopharyngeal swab and was conducted under the GenMark Diagnostics platform. Both tests were conducted in-house at our institution's clinical laboratory under U.S. Food and Drug Administration Emergency-Use Authorization (EUA).
Vilke G.M., Brennan J.J., Cronin A.O, & Castillo E.M. (2020). Clinical Features of Patients with COVID-19: is Temperature Screening Useful?. The Journal of Emergency Medicine, 59(6), 952-956.
+ Open protocol
+ Expand
5

Comparative Study of sCoV and COVID-19 Hospitalizations

Check if the same lab product or an alternative is used in the 5 most similar protocols
This cross-sectional retrospective cohort study included 380 hospitalized adult patients (18 years or older) with sCoV or COVID19 across four AMITA Health hospitals located in the Chicago metropolitan area. A total of 190 patients hospitalized with pneumonia (ICD-10-CM Code J18.9), upper respiratory tract infection (ICD-10-CM Code J06.9) or lower respiratory tract infection (ICD-10-CM Code J22), and a positive respiratory viral panel (BioFire® FilmArray Respiratory Panel) for sCoV from January 1, 2011, to March 31, 2020, were identified by the Electronic Health Records department and thus, no sample size calculation was performed. Those patients were compared with 190 patients randomly selected from a de-identified dataset that included 313 hospitalized adult patients with molecularly confirmed new-onset symptomatic COVID-19 (Abbott™ RealTime™ SARS-CoV-2 assay or Abbott™ ID NOW COVID-19™ assay) admitted from March 1, 2020, to May 25, 2020.
Rodriguez-Nava G., Egoryan G., Dong T., Zhang Q., Hyser E., Poudel B., Yanez-Bello M.A., Trelles-Garcia D.P., Chung C.W., Pyakuryal B., Imani-Ramos T., Trelles-Garcia V.P., Bustamante-Soliz D.S, & Stake J.J. (2022). Comparison of clinical characteristics and outcomes of hospitalized patients with seasonal coronavirus infection and COVID-19: a retrospective cohort study. BMC Infectious Diseases, 22, 618.
+ Open protocol
+ Expand
6

COVID-19 ID Now Assay with NAAT

Check if the same lab product or an alternative is used in the 5 most similar protocols
The COVID-19 ID Now assay (Abbott Diagnostics, Scarborough, MA) was performed on-site following manufacturer instructions for swab-based collections, except for two drops of RTB that were added to the sample chamber before processing the original Ag-RDT collection swab (Fig. 1). The remaining RTB and swab were transported to a central laboratory in the Ag-RDT reaction tube, and 200 μL of viral transport medial (VTM) (Rodoxica, Little Rock, AR) was added to the tube (to ensure sufficient volumes for NAAT testing). Following vortexing for 10 s, 200 μL of VTM/RTB fluid was subjected to a total nucleic acid extraction (TNA) on a MagNA Pure 96 or LC 2.0 instrument (Roche Diagnostics ltd., Roltkreuz, Switzerland), and 5 μL of the 50 μL of eluted TNAs were used as the template for real-time RT-PCR using the TaqPath COVID-19 Combo kit (Life Technologies Corp., Frederick, MD).
LeBlanc J.J., McCracken G.R., Goodall B., Hatchette T.F., Barrett L., Ross J., Davidson R.J, & Patriquin G. (2022). Avoiding False-Positive SARS-CoV-2 Rapid Antigen Test Results with Point-of-Care Molecular Testing on Residual Test Buffer. Microbiology Spectrum, 10(4), e00639-22.
+ Open protocol
+ Expand
7

COVID-19 ID Now Assay with NAAT

Check if the same lab product or an alternative is used in the 5 most similar protocols
The COVID-19 ID Now assay (Abbott Diagnostics, Scarborough, MA) was performed on-site following manufacturer instructions for swab-based collections, except for two drops of RTB that were added to the sample chamber before processing the original Ag-RDT collection swab (Fig. 1). The remaining RTB and swab were transported to a central laboratory in the Ag-RDT reaction tube, and 200 μL of viral transport medial (VTM) (Rodoxica, Little Rock, AR) was added to the tube (to ensure sufficient volumes for NAAT testing). Following vortexing for 10 s, 200 μL of VTM/RTB fluid was subjected to a total nucleic acid extraction (TNA) on a MagNA Pure 96 or LC 2.0 instrument (Roche Diagnostics ltd., Roltkreuz, Switzerland), and 5 μL of the 50 μL of eluted TNAs were used as the template for real-time RT-PCR using the TaqPath COVID-19 Combo kit (Life Technologies Corp., Frederick, MD).
LeBlanc J.J., McCracken G.R., Goodall B., Hatchette T.F., Barrett L., Ross J., Davidson R.J, & Patriquin G. (2022). Avoiding False-Positive SARS-CoV-2 Rapid Antigen Test Results with Point-of-Care Molecular Testing on Residual Test Buffer. Microbiology Spectrum, 10(4), e00639-22.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!